NASDAQ:IMMPIMMUTEP LTD/S News Headlines

$0.67

-0.05 (-6.94 %)

(As of 04/5/2020 11:55 AM ET)

Add

Compare

Today's Range

$0.63

Now: $0.67▼

$0.71

50-Day Range

$0.72

MA: $2.08▼

$3.03

52-Week Range

$0.53

Now: $0.67▼

$3.10

Volume276,922 shs

Average Volume563,961 shs

Market Capitalization$26.13 million

P/E RatioN/A

Dividend YieldN/A

Beta2.09

IMMUTEP LTD/S (NASDAQ IMMP) News Headlines

Source:

Date	Headline
	Immutep down 45% premarket on underwhelming efti data seekingalpha.com - March 25 at 8:07 AM
	The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down www.benzinga.com - March 25 at 8:07 AM
	Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti finance.yahoo.com - March 19 at 8:33 PM
	Immutep Receives Second IND approval for Efti from US FDA finance.yahoo.com - March 9 at 9:09 AM
	The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA www.benzinga.com - February 19 at 8:03 AM
	Those Who Purchased Immutep (ASX:IMM) Shares Five Years Ago Have A 31% Loss To Show For It finance.yahoo.com - December 11 at 10:16 PM
	The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings finance.yahoo.com - October 15 at 11:10 AM
	Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma finance.yahoo.com - October 15 at 11:10 AM
	Immutep Limited (ASX:IMM): When Will It Breakeven? finance.yahoo.com - October 12 at 9:38 PM
	Immutep Completes A$6M Entitlement Offer finance.yahoo.com - August 6 at 9:16 AM
	Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer finance.yahoo.com - July 9 at 9:46 AM
	Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer finance.yahoo.com - June 25 at 10:10 AM
	Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial finance.yahoo.com - June 13 at 9:45 AM
	INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004” finance.yahoo.com - June 6 at 9:38 AM
	Immutep nabs patent in U.S. for eftilagimod alpha in cancer; shares up 49% premarket seekingalpha.com - March 22 at 9:47 AM
	Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation finance.yahoo.com - March 7 at 5:45 PM
	Immutep doses First Patient in TACTI-002 Phase II Trial finance.yahoo.com - March 6 at 9:49 AM
	Immutep to Present at Upcoming Industry Conferences finance.yahoo.com - February 26 at 10:03 AM
	Immutep Enters Into Clinical Trial Collaboration, Service and Supply Agreement With CYTLIMIC finance.yahoo.com - January 7 at 9:23 AM
	Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital - GlobeNewswire globenewswire.com - December 21 at 9:25 AM
	Form 6-K IMMUTEP Ltd For: Dec 19 - StreetInsider.com www.streetinsider.com - December 21 at 9:25 AM
	Form 424B5 IMMUTEP Ltd - StreetInsider.com www.streetinsider.com - December 21 at 9:25 AM